Related Experiment Video

Updated: Mar 13, 2026

Generation of Multivirus-specific T Cells to Prevent/treat Viral Infections after Allogeneic Hematopoietic Stem Cell Transplant
08:52

Generation of Multivirus-specific T Cells to Prevent/treat Viral Infections after Allogeneic Hematopoietic Stem Cell Transplant

Published on: May 27, 2011

17.9K

Current role of ATG in GVHD prevention: optimizing post-transplantation outcomes through combination with PTCY

Maria Liga1, Dimitrios Tsokanas1, Angeliki N Georgopoulou1

  • 1Hematology Division and Bone Marrow Transplantation Unit, Institute of Cell Therapy, University of Patras, Rio 26504, Greece.

Current Opinion in Immunology
|March 11, 2026
PubMed

Graft versus host disease (GVHD) is one of the major complications of allogeneic hematopoietic cell transplantation (allo-HCT), contributing significantly to post-transplant morbidity and mortality. Anti-thymocyte globulin (ATG) is a widely used GVHD prophylaxis in combination with a calcineurin inhibitor and an antimetabolite. Post-transplant cyclophosphamide (PTCy) has been a milestone in haploidentical transplantation, and its use has expanded to allo-HCT performed from matched related and unrelated donors with notable success. In this review, we discuss how post-transplantation outcomes can be optimized through a combination of ATG with PTCY. We summarize the biological rationale, current clinical evidence, and remaining uncertainties regarding this dual in vivo T-cell depletion strategy, highlighting its potential to enhance GVHD control, reduce immunosuppressive burden, and improve survival across different donor settings.

More Related Videos

Induction of Alloantigen-specific Anergy in Human Peripheral Blood Mononuclear Cells by Alloantigen Stimulation with Co-stimulatory Signal Blockade11:55

Induction of Alloantigen-specific Anergy in Human Peripheral Blood Mononuclear Cells by Alloantigen Stimulation with Co-stimulatory Signal Blockade

Published on: March 14, 2011

15.0K
Bone Marrow Transplantation Platform to Investigate the Role of Dendritic Cells in Graft-versus-Host Disease08:05

Bone Marrow Transplantation Platform to Investigate the Role of Dendritic Cells in Graft-versus-Host Disease

Published on: March 17, 2020

8.4K

Related Concept Videos

Tumor Immunotherapy01:27

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
2.1K
Cancer Vaccines01:30

Cancer Vaccines

Cancer treatment vaccines are a rapidly evolving field that offers a promising approach to immunotherapy. Unlike traditional vaccines that prevent diseases, cancer treatment vaccines are designed to treat existing cancers by stimulating the immune system to recognize and attack cancer cells.
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...
1.2K
Pharmacogenetics of Phase II Enzymes: N-acetyltransferase, Thiopurine S-methyltransferase, UDP-glucuronosyltransferase01:27

Pharmacogenetics of Phase II Enzymes: N-acetyltransferase, Thiopurine S-methyltransferase, UDP-glucuronosyltransferase

Phase II biotransformation reactions are essential for detoxifying and eliminating xenobiotics, including many pharmaceutical compounds. These reactions typically involve conjugation, the covalent attachment of polar endogenous groups such as glucuronic acid, sulfate, methyl, or acetyl moieties to functional groups introduced during Phase I metabolism. The resulting conjugates are more water-soluble, enabling efficient renal or biliary excretion.The major classes of Phase II enzymes include...
55